Published in Women's Health Weekly, February 16th, 2006
W. Guo and colleagues, M.D. Anderson Cancer Center, wrote, "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and oncolytic adenovirotherapy have been investigated extensively in xerographic human tumor models established in immunocompromised nude mice. However, the effects of these therapies on syngeneic murine tumors in immunocompetent settings were not well documented."
"We hypothesized that TRAIL gene therapy used with an oncolytic adenovirus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly